GILD - Gilead Sciences, Inc.
| Previous Close | 64.22 |
| Open | 64.07 |
| Bid | 62.51 x 900 |
| Ask | 62.82 x 900 |
| Day's Range | 62.19 - 64.67 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 7,488,696 |
| Avg. Volume | 6,153,473 |
| Market Cap | 79.166B |
| Beta (3Y Monthly) | 1.17 |
| PE Ratio (TTM) | 13.55 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.52 (3.93%) |
| Ex-Dividend Date | 2019-09-12 |
| 1y Target Est | N/A |
- Business Wire
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium.
- Business Wire
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA.
CNW GroupQuébec Provides Access to Biktarvy® for the Treatment of HIV
Québec Provides Access to Biktarvy® for the Treatment of HIV
- Business Wire
China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Gilead Sciences, Inc. (GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. In China, Biktarvy is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. “Biktarvy offers high rates of efficacy, high barriers to resistance and a demonstrated tolerability profile, underscoring its role as an important new treatment option for a broad range of patients in China,” said Professor Taisheng Li, Director of Infectious Disease Department, Peking Union Medical College Hospital.
- Business Wire
Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
F/TAF) for the proposed indication of pre-exposure prophylaxis (PrEP) in men and transgender women (TGW) who have sex with men by a vote of 16 to 2. “We appreciate the advisory committee’s thoughtful review and discussion of the data during today’s meeting and look forward to collaborating with FDA to make this potential new prevention option available to people at risk of HIV in the United States,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences.
CNW GroupOntario Provides Access to Biktarvy® for the Treatment of HIV
Ontario Provides Access to Biktarvy® for the Treatment of HIV
- Business Wire
Gilead Sciences Announces Third Quarter 2019 Dividend
Gilead Sciences, Inc. today announced that the company’s Board of Directors has declared a cash dividend of $0.63 per share of common stock for the third quarter of 2019.
- Business Wire
Gilead Sciences Announces Second Quarter 2019 Financial Results
- Product Sales of $5.6 billion - - Diluted EPS of $1.47 per share - - Non-GAAP Diluted EPS of $1.82 per share - - Revised Full Year 2019 Guidance -
- ACCESSWIRE
Gilead Sciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July, 30 2019 / Gilead Sciences, Inc. (NASDAQ: GILD ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30 PM ...
- Business Wire
Gilead Announces Latest Data in Ongoing HIV Cure Research Program
The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure.
- Business Wire
Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®
F/TAF) for HIV pre-exposure prophylaxis (PrEP). F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City.
- Business Wire
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
Gilead Sciences, Inc. today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo tide or non-nucleo tide reverse transcriptase inhibitors .
- Business Wire
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
Gilead Sciences, Inc. (GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV.
- Business Wire
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
Gilead Sciences, Inc. (GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.
- Business Wire
Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
Gilead Sciences, Inc. today announced that new data from the company’s HIV research and development programs will be presented at the 10th International AIDS Society Conference on HIV Science being held in Mexico City from July 21-24.
- Business Wire
Gilead Sciences Announces Changes to Senior Leadership Team
Gilead Sciences, Inc. (GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.
- Business Wire
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Gilead Sciences, Inc. (GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.
- Business Wire
Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call.
- Business Wire
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Kite, a Gilead Company , today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
- GlobeNewswire
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
- Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment - - Gilead Gains Access to Galapagos` Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of ...
- Business Wire
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
- Business Wire
Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
Gilead Sciences, Inc. (GILD) today announced that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team. Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology.
- Business Wire
Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada.
- GlobeNewswire
GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR
As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019. Filgotinib is an investigational agent and not approved anywhere globally. Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.